

In **Pulmonary arterial hypertension...**

# INTRABON

Bosentan 62.5mg TABLET

DUAL ENDOTHELIN  
RECEPTOR ANTAGONIST

- Proven to reduce mortality & morbidity in PAH
- Improves the 6-min walk distance & also dyspnea on exercise
- Prolongs survival & postpone the introduction of prostanoid vasodilators
- Increases the time to clinical worsening & reduces the proportion of patients in WHO functional class IV<sup>1</sup>
- Improves all clinical & hemodynamic parameters

1. N Engl J Med 2002; 346:896-903



## Expert in managing PAH



# PULMONARY ARTERIAL HYPERTENSION

a chronic life-threatening condition



THE SURVIVAL RATE IS 40-50% AT 2 YEARS  
AFTER THE ONSET OF SYMPTOMS WITH A  
MEDIAN LIFE EXPECTANCY OF 2.8 YEARS<sup>1</sup>

# INTRABON

Bosentan 62.5mg TABLET


In **Pulmonary arterial hypertension...**

# INTRABON

**Bosentan 62.5mg TABLET**

- 🔥 **Dual competitive antagonist** of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors<sup>1</sup>
- 🔥 **Reduces mean pulmonary artery pressure, pulmonary vascular resistance & mean arterial pressure**<sup>2</sup>
- 🔥 **Safe & well tolerated** in adults with pulmonary arterial hypertension associated with congenital heart disease<sup>3</sup>
- 🔥 **Improves exercise capacity** & increases the time to clinical worsening in patients with severe pulmonary arterial hypertension<sup>4</sup>
- 🔥 **Improves prognosis & activities of daily living** without worsening respiratory failure in idiopathic pulmonary fibrosis patients<sup>5</sup>

1. Vasc Health Risk Manag. 2007 Dec; 3(6): 887-9002. Circulation. 2000;102:411-418  
3. Heart. 2007 Aug;93(8):974-64. N Engl J Med 2002; 346:896-903  
5. BMC Pulmonary Med Vol 17, Article No: 200 (2017)



**Expert in managing PAH**